Abstract
We describe the results of treatment with 2'-deoxycoformycin (DCF) in 68 patients with post-thymic (mature) T-cell malignancies. These included: prolymphocytic leukaemia (T-PLL), 31, HTLV-1 + adult T-cell leukaemia/lymphoma (ATLL), 20, cutaneous T-cell lymphoma (CTCL), comprising mycosis fungoides and Sezary syndrome, 13, and large granular lymphocytic leukaemia, four. Two-thirds of patients were refractory to previous therapy, which included four drug combinations. DCF was given intravenously at 4 mg m-2 weekly for the first 4 weeks and then every 2 weeks until maximal response. Toxicity was very low with only one death resulting from prolonged neutropenia. Overall response rates, partial (PR) and complete. (CR), were 38%, with variations according to diagnosis. Best responses, 54%, were seen in CTCL but limited to Sezary patients, one CR, six PR, whilst none of the mycosis fungoides responded. Responses in T-PLL were recorded in 48% including three CR (of 8-12 months' duration unmaintained) and 12 PR. Fifteen per cent of responses were seen in ATLL. The only ATLL responders - two CR, one PR - were those patients who received combination chemotherapy prior to DCF, with reduction of tumour bulk but short of PR. When results were analysed according to membrane phenotypes it was apparent that responses were seen mainly in cases with CD4+, CD8- T cells -22 of 47 (47%) - contrasting with only three of 19 (16%) with other T-cell phenotypes. We conclude that DCF is a useful therapy for the treatment of T-cell leukaemias, in particular Sezary syndrome and T-PLL, and should play a part in strategies to improve the natural history of this group of lymphoid malignancies.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Begleiter A., Glazer R. I., Israels L. G., Pugh L., Johnston J. B. Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2'-deoxycoformycin in vivo and in vitro. Cancer Res. 1987 May 1;47(9):2498–2503. [PubMed] [Google Scholar]
- Dearden C. E., Matutes E., Hoffbrand A. V., Ganeshaguru K., Brozovic M., Williams H. J., Traub N., Mills M., Linch D. C., Catovsky D. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies. Br Med J (Clin Res Ed) 1987 Oct 10;295(6603):873–875. doi: 10.1136/bmj.295.6603.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ho A. D., Ganeshaguru K., Knauf W. U., Dietz G., Trede I., Hunstein W., Hoffbrand A. V. Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood. 1988 Dec;72(6):1884–1890. [PubMed] [Google Scholar]
- Mattock C., Anderson N. A., Sheldon C. D., Rustin M. H., Hoffbrand B. I. Spontaneous remission and relapse in adult T cell lymphoma/leukaemia associated with HTLV-I. Br Med J (Clin Res Ed) 1986 May 3;292(6529):1171–1172. doi: 10.1136/bmj.292.6529.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell B. S., Edwards N. L., Koller C. A. Deoxyribonucleoside triphosphate accumulation by leukemic cells. Blood. 1983 Aug;62(2):419–424. [PubMed] [Google Scholar]
- O'Dwyer P. J., Wagner B., Leyland-Jones B., Wittes R. E., Cheson B. D., Hoth D. F. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med. 1988 May;108(5):733–743. doi: 10.7326/0003-4819-108-5-733. [DOI] [PubMed] [Google Scholar]
- Smyth J. F., Prentice H. G., Proctor S., Hoffbrand A. V. Deoxycoformycin in the treatment of leukemias and lymphomas. Ann N Y Acad Sci. 1985;451:123–128. doi: 10.1111/j.1749-6632.1985.tb27102.x. [DOI] [PubMed] [Google Scholar]